Safety and Efficacy Assessment Treatment Trials of Emixustat Hydrochloride

Inclusion criteria

• Males or females, age ≥55 years.
• Clinical diagnosis of GA associated with AMD
• Able and willing to provide written informed consent.
• Able to reliably administer oral medication by self or with available assistance.

Exclusion criteria

• Active CNV or presence of an active ocular disease.
• Known serious allergy to the fluorescein sodium for injection in angiography.
• Pre-specified laboratory abnormalities at screening.
• Treatment with any investigational study drug within 30 days of screening or device (within 60 days of screening)
• History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding
• Female subjects who are pregnant or lactating.
• Female subjects of childbearing potential and male subjects who are not surgically sterile who are not willing to practice a medically accepted method of birth control from screening through 30 days after completion of the study.
• Unstable or poorly controlled medical or ophthalmic conditions